CKD Bio Corp.
Financials
Valuation Metrics
CKD Bio Corp.'s Market Cap is ₩751B. At end of 2025 it was ₩1116B. Ranked #1441 of 2,436 in KR market (top 59%), #626 of 787 on KOSPI (top 80%), #157 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 67%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 75.10B KRW | KR#1,441/2,436 Sec#157/234 |
| Revenue | 158.24B KRW | KR#1,142/2,436 Sec#70/234 |
| Net Income | -5.82B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 298.38B KRW | KR#1,020/2,436 Sec#70/234 |
| Net Assets | 125.00B KRW | KR#1,245/2,436 Sec#100/234 |
| Employees | 509 | KR#487/2,436 Sec#41/234 |
| Value | ||
| P/B | 0.60x | KR#984/2,436 Sec#48/234 |
| P/S | 0.47x | KR#888/2,436 Sec#36/234 |
| FCF Yield | -14.58% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -4.65% | KR#1,733/2,436 Sec#128/234 |
| ROA | -1.95% | KR#1,701/2,436 Sec#122/234 |
| Op. Margin | -0.12% | KR#1,601/2,436 Sec#114/234 |
| Revenue Growth | -4.29% | KR#1,672/2,436 Sec#156/234 |
| Earnings Growth | -325.41% | KR#1,575/2,436 Sec#102/234 |
| Financial Health | ||
| Debt Ratio | 138.71% | KR#1,012/2,436 Sec#117/234 |
| Total Debt | 145.85B KRW | KR#589/2,436 Sec#31/234 |
| FCF | -10.95B KRW | KR#1,742/2,436 Sec#153/234 |
| Cash | 955.7M KRW | KR#2,340/2,436 Sec#225/234 |
| Current Ratio | 1.10x | KR#1,702/2,436 Sec#172/234 |
| Dividend | ||
| Div. Yield | 0.76% | KR#1,216/2,436 Sec#75/234 |
| Div. Growth | -0.00% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | -38.33% | KR#1,796/2,436 Sec#157/234 |
| 1M Return | 1.33% | KR#848/2,436 Sec#67/234 |
| From 52W High | -50.49% | KR#1,204/2,436 Sec#101/234 |
| 1Y MDD | -50.20% | KR#941/2,436 Sec#78/234 |
| Trading | ||
| Volume | 15,174 shares | KR#2,117/2,436 Sec#210/234 |
| Foreign Own. | 1.01% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -1,060 KRW | KR—/2,436 Sec—/234 |
| BPS | 22,785 KRW | KR#461/2,436 Sec#30/234 |
Company Info
Chong Kun Dang Bio was established in 2001 through a spin-off of the fermentation and refined raw materials business. It supplies over 30 types of active pharmaceutical ingredients (APIs), including antibiotics, to over 50 countries worldwide using advanced fermentation facilities. The company produces probiotic raw materials and finished products with its fermentation and patented technologies, and has launched botulinum toxin products from a dedicated plant in Osong. Chong Kun Dang Bio is focusing on obtaining patents for regulatory market entry, achieving cGMP certification for key products, building microbiome CDMO facilities, and developing new drugs for conditions such as Alzheimer's. Chong Kun Dang Bio was established in 2001 and is headquartered in Seodaemun-gu, Seoul.